Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
Parkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkinson’s disease diagnosis is typically done when a sign...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Neural Regeneration Research |
| Subjects: | |
| Online Access: | http://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=12;spage=2637;epage=2642;aulast=Mourtzi |
| _version_ | 1811295781806669824 |
|---|---|
| author | Theodora Mourtzi Ilias Kazanis |
| author_facet | Theodora Mourtzi Ilias Kazanis |
| author_sort | Theodora Mourtzi |
| collection | DOAJ |
| description | Parkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkinson’s disease diagnosis is typically done when a significant percentage of the dopaminergic neurons is already lost. In neurodegenerative disorders, some therapeutic strategies could be effective only at inhibiting further degeneration; on the other hand, cell replacement therapies aim at replacing lost neurons, an approach that would be ideal for the treatment of Parkinson’s disease. Many cell replacement therapies have been tested since the 1970s in the field of Parkinson’s disease; however, there are still significant limitations prohibiting a successful clinical application. From the first fetal midbrain intrastriatal graft to the most recent conversion of astrocytes into dopaminergic neurons, we have gained equally, significant insights and questions still looking for an answer. This review aims to summarize the main milestones in cell replacement approaches against Parkinson’s disease. By focusing on achievements and failures, as well as on the additional research steps needed, we aim to provide perspective on how future cell replacement therapies treats Parkinson’s disease. |
| first_indexed | 2024-04-13T05:38:40Z |
| format | Article |
| id | doaj.art-9c0dd1b2c1a7426fb39c82861ad2b233 |
| institution | Directory Open Access Journal |
| issn | 1673-5374 |
| language | English |
| last_indexed | 2024-04-13T05:38:40Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Neural Regeneration Research |
| spelling | doaj.art-9c0dd1b2c1a7426fb39c82861ad2b2332022-12-22T03:00:11ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53742022-01-0117122637264210.4103/1673-5374.336137Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?Theodora MourtziIlias KazanisParkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkinson’s disease diagnosis is typically done when a significant percentage of the dopaminergic neurons is already lost. In neurodegenerative disorders, some therapeutic strategies could be effective only at inhibiting further degeneration; on the other hand, cell replacement therapies aim at replacing lost neurons, an approach that would be ideal for the treatment of Parkinson’s disease. Many cell replacement therapies have been tested since the 1970s in the field of Parkinson’s disease; however, there are still significant limitations prohibiting a successful clinical application. From the first fetal midbrain intrastriatal graft to the most recent conversion of astrocytes into dopaminergic neurons, we have gained equally, significant insights and questions still looking for an answer. This review aims to summarize the main milestones in cell replacement approaches against Parkinson’s disease. By focusing on achievements and failures, as well as on the additional research steps needed, we aim to provide perspective on how future cell replacement therapies treats Parkinson’s disease.http://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=12;spage=2637;epage=2642;aulast=Mourtziendogenous; neurodegenerative disease; neurogenesis; neurotrophic factors; parkinson’s disease; stem cells; transdifferentiation; transplantations |
| spellingShingle | Theodora Mourtzi Ilias Kazanis Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going? Neural Regeneration Research endogenous; neurodegenerative disease; neurogenesis; neurotrophic factors; parkinson’s disease; stem cells; transdifferentiation; transplantations |
| title | Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going? |
| title_full | Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going? |
| title_fullStr | Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going? |
| title_full_unstemmed | Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going? |
| title_short | Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going? |
| title_sort | endogenous versus exogenous cell replacement for parkinson s disease where are we at and where are we going |
| topic | endogenous; neurodegenerative disease; neurogenesis; neurotrophic factors; parkinson’s disease; stem cells; transdifferentiation; transplantations |
| url | http://www.nrronline.org/article.asp?issn=1673-5374;year=2022;volume=17;issue=12;spage=2637;epage=2642;aulast=Mourtzi |
| work_keys_str_mv | AT theodoramourtzi endogenousversusexogenouscellreplacementforparkinsonsdiseasewhereareweatandwherearewegoing AT iliaskazanis endogenousversusexogenouscellreplacementforparkinsonsdiseasewhereareweatandwherearewegoing |